Metraipolis › archive › dc_ab611deb5ef0
Avutometinib/defactinib — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Avutometinib/defactinib
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T13:32:47.441Z
- SHA-256 of the archived text
d07e9d5a69e45991165f69c7a494c5f6539e51ab58d518126eb1c7f8deb17df3- Stable URL of this page
https://metraipolis.com/documento/dc_ab611deb5ef0
How to cite
Avutometinib/defactinib — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Avutometinib/defactinib (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_ab611deb5ef0 (Metraipolis archive dc_ab611deb5ef0, sha256 d07e9d5a69e45991165f69c7a494c5f6539e51ab58d518126eb1c7f8deb17df3)
BibTeX
@misc{dcab611deb5ef0,
title = {Avutometinib/defactinib — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Avutometinib/defactinib},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_ab611deb5ef0; sha256 d07e9d5a69e45991165f69c7a494c5f6539e51ab58d518126eb1c7f8deb17df3},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Avutometinib/defactinib. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Avutometinib/defactinib, sold under the brand name Avmapki Fakzynja Co-Pack, is a co-packaged medication used for the treatment of ovarian cancer. It contains the anti-cancer medications avutometinib, a kinase inhibitor, as the potassium salt; and defactinib, a kinase inhibitor, as the hydrochloride. It is taken by mouth. The most common adverse reactions including laboratory abnormalities, include increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. Avutometinib/defactinib was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Avutometinib/defactinib» — https://en.wikipedia.org/wiki/Avutometinib/defactinib Wikidata Q134622175: «combination cancer medication» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q134622175 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Avutometinib/defactinib?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1365399471, consultata il 2026-11-10T13:29:22.390Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 0320d0968ebcaba88a9367f61f9dd81e356229f98889b0d3da7dd6f4a9ef919a